AbbVie’s Business Development, Cancer Plans Not Put Off By Stemcentrx Disappointments

At J.P. Morgan, AbbVie said the clinical struggles of Rova-T won’t alter its deal-making plans and leave it with plenty of solid tumor possibilities. The pharma took a $4bn write-off of the Stemcentrx deal on Jan. 4.

Business concept illustration of a businessman being guided by a hand holding a flashlight uncovering arrow sign.

AbbVie Inc.’s $5.8bn purchase of Stemcentrx Inc. in 2016 was intended to add promising solid tumor oncology candidates to its pipeline, but after multiple clinical trial disappointments with lead candidate rovalpituzumab tesirine (Rova-T), the pharma recently took a $4bn impairment charge on the deal. At the J.P. Morgan Healthcare Conference, AbbVie President Michael Severino said that result won’t affect the firm’s deal-making plans and that AbbVie still has significant solid tumor assets in-house.

The Chicago-area drug maker halted the Phase III TAHOE study of Rova-T in second-line small cell lung cancer (SCLC) in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By 

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By 

The Belgian drugmaker is boosting its biologics capacity over the pond.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By 

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.

More from Business